Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

2 results
12:00 AM, Oct 03, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Odalasvir: Interim Phase IIa data

genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335
odalasvir and Olysio simeprevir. In cohort 1 (n=20), once-daily 400 mg AL-335 plus 50 mg …
the end of treatment in 100% of patients. In cohort 2 (n=20), once-daily 800 mg AL-335
12:00 AM, Oct 03, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

AL-335: Interim Phase IIa data

genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335
odalasvir and Olysio simeprevir. In cohort 1 (n=20), once-daily 400 mg AL-335 plus 50 mg odalasvir …
the end of treatment in 100% of patients. In cohort 2 (n=20), once-daily 800 mg AL-335